http://www.arrowres.com/ Arrowhead Research Corp.: Nanotech with a point en-us Copyright 2005, Arrowhead Research Corporation Mon, 10 Mar 2008 Mon, 10 Mar 2008 60 http://www.arrowres.com/images/links/logo_about1.gif http://www.arrowres.com/ 100 88 Arrowhead Research Corp.: Nanotech with a point http://www.arrowres.com/publications/080506045447.html Pasadena, CA—May 6, 2008--Arrowhead Research Corporation announced today the sale of its majority-owned subsidiary, Aonex Technologies, to AmberWave Systems. Under the terms of the deal, AmberWave will pay Aonex shareholders up to $7.95M in earn-out payments, plus a running royalty on sales of solar products incorporating Aonex’s technology. Thu, 6 May 2008 04:00:00 PST http://www.arrowres.com/publications/080422045447.html Menlo Park, Calif. - April 22, 2008 - Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today the first flight of an aircraft incorporating Unidym’s carbon nanotubes into its airframe for increased strength and flexibility to combat the effects of aerodynamic stress and engine vibration. On April 11th Avalon Aviation's Giles G-200 aircraft flew with Unidym's carbon nanotubes incorporated into its carbon fiber composite engine cowling. The Giles G-200 is a high performance, single engine fully aerobatic carbon composite aircraft. Thu, 22 Apr 2008 04:00:00 PST http://www.arrowres.com/publications/080421045447.html PASADENA, Calif. - April 21, 2008 - Calando Pharmaceuticals, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug application (IND) for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase—a clinically-validated cancer target—formulated with Calando’s proprietary RONDEL™ (RNAi/Oligonucleotide Nanoparticle Delivery) polymer delivery system. The FDA approval allows the initiation of a Phase I trial that will be conducted at the UCLA Jonsson Cancer Center (UCLA) in Los Angeles, California, and the South Texas Accelerated Research Therapeutics (START) clinic in San Antonio, Texas. It will be led by Drs. Antoni Ribas (UCLA) and Anthony Tolcher (START). Thu, 21 Apr 2008 04:00:00 PST http://www.arrowres.com/publications/080417045447.html Pasadena, CA - April 17, 2008 - Insert Therapeutics, Inc., a majority owned subsidiary of Arrowhead Research Corporation (ARWR), announced today that it has filed with the U.S. Food and Drug Administration to initiate a Phase II clinical trial evaluating the safety and efficacy of its drug candidate, IT-101 in patients with ovarian cancer. In women who receive a 2nd course of chemotherapy, nearly 75% will achieve some degree of disease stabilization. However, most will experience a recurrence of their cancer within 9 to 12 months after treatment. For these women, the current standard care is to “watch and wait” until disease progression occurs. Thu, 17 Apr 2008 04:00:00 PST http://www.arrowres.com/publications/080318045447.html MENLO PARK, Calif.–March 18, 2008–Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced today the formation of a spin-off company, Ensysce Biosciences Inc., that will focus on research into the medical therapeutic applications of carbon nanotubes. Unidym has licensed its extensive nanotechnology patent portfolio to Ensysce for this field of use and in return holds a significant equity position in Ensysce. The inception of Ensysce stems from the final research interests of the late Dr. Richard Smalley, the 1996 Nobel Laureate for Chemistry from Rice University, who was among the pioneers in considering the potential therapeutic applications for carbon nanotubes. Unidym acquired rights to Dr. Smalley's work in carbon nanotechnology through a corporate merger in April of last year. Wed, 18 Mar 2008 04:00:00 PST http://www.arrowres.com/publications/080314045447.html PASADENA, Calif.–March 14, 2008–On March 14, 2008, Arrowhead Research Corporation's (NASDAQ: ARWR) Chief Executive Officer, Christopher Anzalone, presented a slide show entitled "Creating Value by Building Nanobusiness from Nanoscience" following Arrowhead's Annual Meeting of Stockholders. Dr. Anzalone began by describing the market opportunity presented by advances in nanoscience and Arrowhead's key value drivers. He described the advantages of Arrowhead's business model and his vision of the company as an as an institutional entrepreneur. Wed, 14 Mar 2008 04:00:00 PST http://www.arrowres.com/publications/080313045447.html PASADENA, Calif.–March 13, 2008–Arrowhead Research Corporation (NASDAQ: ARWR) announced today that its majority owned subsidiary, Calando Pharmaceuticals, a leading siRNA therapeutics company, submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration to initiate a Phase I clinical trial using their lead anti-cancer compound, CALAA-01. Dr. Anzalone will discuss the IND filing, Calando's clinical plans, and Arrowhead's other 2008 objectives in a webcast presentation following the Annual Meeting of Shareholders today at 10:30 AM PT. Wed, 13 Mar 2008 04:00:00 PST http://www.arrowres.com/publications/080312045447.html MENLO PARK, Calif.–March 12, 2008–Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered into a joint development agreement with Nippon Kayaku, to integrate Unidym's printable transparent electrodes into Nippon Kayaku's thin film solar cells. Nippon Kayaku Co. is a diversified Japanese chemical company with over $1.4B in 2007 sales that is bringing its global development and manufacturing capabilities to the rapidly developing thin film solar cell market. Wed, 12 Mar 2008 04:00:00 PST http://www.arrowres.com/publications/080305045447.html PASADENA, Calif.–March 5, 2008–Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Dr. Christopher Anzalone, Arrowhead’s Chief Executive Officer and President, will present the Company’s strategic plan and objectives for 2008 at 10:30 am PT on March 13, 2008, following the scheduled Annual Meeting of Shareholders. Wed, 5 Mar 2008 04:00:00 PST http://www.arrowres.com/publications/080228041756.html PASADENA, Calif.–February 28, 2008–Arrowhead Research Corporation (Nasdaq: ARWR) announced today a fundamental streamlining of its majority-owned subsidiaries, Calando Pharmaceuticals and Insert Therapeutics. Arrowhead will assume active management of the companies and focus resources on bringing multiple products to the clinic as rapidly as possible. Arrowhead’s expanded role is intended to make Calando and Insert operations more efficient. This is a process that includes a merger of the companies, which has been submitted to shareholders. Larry Stambaugh has stepped down from his role as CEO of both companies but will remain a consultant to help establish partnerships with larger pharmaceutical companies. Thu, 28 Feb 2008 04:00:00 PST http://www.arrowres.com/publications/080212043853.html PASADENA, Calif.–February 12, 2008–Arrowhead Research Corporation (Nasdaq: ARWR) announced the appointment of Dr. Chad Mirkin to its newly established Board of Scientific Strategy. Tue, 12 Feb 2008 04:00:00 PST http://www.arrowres.com/publications/080211042951.html MENLO PARK, Calif.–February 11, 2008–Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it is expanding its Houston manufacturing operations to meet the growing demand for high quality carbon nanotubes used by both its transparent electrode business and the market in general. Unidym, which recently merged with Carbon Nanotechnologies, Inc. (CNI), has its headquarters in Menlo Park, California and carbon nanotube manufacturing operations in Houston, Texas. Mon, 11 Feb 2008 04:00:00 PST http://www.arrowres.com/publications/080128043049.html PASADENA, Calif.–January 28, 2008–Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Mauro Ferrari to its newly established Board of Scientific Strategy. He is one of the most well-known experts in leveraging nanotechnology to treat and diagnose cancer. Dr. Ferrari will serve as a Director of Scientific Strategy and will be integral in building out the new advisory board and guiding Arrowhead’s operations and strategic plan. Mon, 28 Jan 2008 04:00:00 PST http://www.arrowres.com/publications/080122041047.html PASADENA, Calif.–January 22, 2008–Arrowhead Research Corporation (Nasdaq: ARWR), announced today that its President & CEO, Dr. Christopher Anzalone, will present at the 7th Annual Rice Alliance Nanotechnology Forum on January 24, 2008 at 4:00 pm CT in Houston, Texas. Dr. Anzalone will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences. Tue, 22 Jan 2008 04:00:00 PST http://www.arrowres.com/publications/071227043239.html PASADENA, Calif.–December 27, 2007–Arrowhead Research Corporation (Nasdaq: ARWR), announced today that its President & CEO, Christopher Anzalone, will present at the 10TH Annual Needham Growth Stock Conference on Wednesday, January 9, 2008 at 3:00 pm ET in New York City. Dr. Anzalone will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences. Thu, 27 Dec 2007 04:00:00 PST http://www.arrowres.com/publications/071205045633.html Menlo Park, Calif.– December 5, 2007 – Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced that Unidym’s Chief Technology Officer, Dr. Paul Drzaic, will be presenting an invited lecture today at the Fraunhofer IZM Munich Forum 2007 'be-flexible' Thin Semiconductor Devices on December 05, 2007. Dr. Drzaic’s presentation “Is there a Role for Silicon Microelectronics in an Increasingly-flexible World?” will take a broad view of the emergence of flexible electronic devices, and compare the potential of incumbent silicon technologies with emerging microelectronic technologies. He will also describe how novel materials, like Unidym’s carbon nanotube devices, enable a number of new flexible product applications in this increasingly important area of technology. The `be-flexible´ Forum was initiated by Fraunhofer IZM-Munich to face present and future challenges concerning research, technology, integration, manufacturing and trends in the fast evolving world of flexible electronics. Wed, 5 Dec 2007 04:00:00 PST http://www.arrowres.com/publications/071204043227.html PASADENA, Calif.–December 4, 2007–Arrowhead Research Corporation (Nasdaq: ARWR), announced today that majority owned subsidiary, Unidym, Inc., has completed a $10.4 million Series C financing. Several financial institutions participated in the round, along with strategic investors Tokyo Electron Ventures and Battelle Memorial Institute. Arrowhead made a $3 million follow on investment. Tue, 4 Dec 2007 04:00:00 PST http://www.arrowres.com/publications/071203044423.html PASADENA, Calif.– December 3, 2007 – Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Christopher Anzalone as its new President and Chief Executive Officer effective December 1, 2007. Dr. Anzalone was also appointed to Arrowhead’s Board of Directors on the same date. Concurrently, Arrowhead is beginning the process to acquire Benet Group LLC, a private equity firm founded and led by Dr. Anzalone as a vehicle to build new nanobiotechnology companies. Arrowhead’s founder and former CEO, R. Bruce Stewart, will continue to serve as Executive Chairman of the Board. Mon, 3 Dec 2007 04:00:00 PST http://www.arrowres.com/publications/071129045537.html Menlo Park, Calif. – November 29, 2007 – Unidym Inc, a majority owned subsidiary of Arrowhead Research Corporation (Nasdaq: ARWR), announced today that Unidym's founder, Professor George Gruner, has been selected as a visionary Technology Pioneer for 2008 by the World Economic Forum and has been invited to speak at the upcoming WEF Technology Pioneers Conference in Davos, Switzerland this January. Unidym is a leader in the development and manufacture of carbon nanotubes for applications in the electronics industry. Unidym, which recently merged with Carbon Nanotechnologies, Inc. (CNI), possesses a foundational patent portfolio that covers nearly every aspect of carbon nanotube manufacturing and processing. Thu, 29 Nov 2007 04:00:00 PST http://www.arrowres.com/publications/071127042029.html Menlo Park, Calif.– November 27, 2007 – Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced that Unidym’s Chief Technology Officer, Dr. Paul Drzaic, will be presenting an invited lecture today at the Materials Research Society in Boston, MA. Dr. Drzaic’s presentation, entitled “Carbon Nanotube Network, a New Electronic Material” will provide a perspective on some exciting opportunities in large area and flexible electronic devices enabled by carbon nanotube technology. Tue, 27 Nov 2007 04:00:00 PST http://www.arrowres.com/publications/071102044748.html PASADENA, Calif.–November 2, 2007– Arrowhead Research Corporation (Nasdaq: ARWR), announced today that its Chairman and CEO, R. Bruce Stewart, has been selected to present at Global Crown Capital’s Nanotechnology Investment Conference in San Francisco on Thursday, November 8, 2007. Mr. Stewart’s presentation entitled “Nanotechnology: Here and Now” will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences. Fri, 2 Nov 2007 04:00:00 PST http://www.arrowres.com/publications/071101045728.html PASADENA, Calif.– November 1, 2007 – Arrowhead Research Corporation (Nasdaq: ARWR), announced today that its Chairman and CEO, R. Bruce Stewart, will present at the AeA Classic Financial Conference, Session II, in Monterey on Tuesday, November 6, and Wednesday, November 7, 2007. Mr. Stewart’s presentation entitled “Nanotechnology: Here and Now” will highlight how Arrowhead’s unique business model leverages university nanotechnology into capital efficient nanotech companies making products for electronics, energy and life sciences. Thu, 1 Nov 2007 04:00:00 PST http://www.arrowres.com/publications/071031042325.html PASADENA, Calif.– October 31, 2007 – Arrowhead Research Corporation (NASDAQ: ARWR), announced today that Larry G. Stambaugh has been appointed as President and Chief Executive Officer of two of its majority-owned subsidiaries, Calando Pharmaceuticals, Inc. and Insert Therapeutics, Inc., and that a merger between the two companies is being pursued. Both companies are developing anti-cancer drugs. Insert is already in clinical studies with its first drug candidate and Calando is preparing to file an investigational new drug (IND) application for its first RNAi-based drug candidate. Wed, 31 Oct 2007 04:00:00 PST http://www.arrowres.com/publications/071025044813.html PASADENA, Calif.– October 25, 2007 – Arrowhead Research Corporation (Nasdaq: ARWR), announced today that it has provided $2.4 million in additional capital to wholly-owned subsidiary, Tego Biosciences Corporation. Tego is developing and commercializing therapeutics and other products based on the antioxidant properties of modified fullerenes. Dr. Russ Lebovitz has been appointed CEO to chart the strategic direction and guide the operations of the new nano-biotechnology company. Dr. Lebovitz served previously as CEO of C Sixty, Inc., the company that pioneered the technology now owned by Tego. Thu, 25 Oct 2007 04:00:00 PST http://www.arrowres.com/publications/071016045924.html Menlo Park, Calif.– October 16, 2007 – Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced that Unidym’s President and CEO Arthur L. Swift will be speaking today at the Lux Executive Summit in Cambridge, MA. Mr. Swift’s presentation, entitled “Nanotechnology in the Post Silicon Era,” will detail Unidym’s view of carbon nanotechnology and the nanotube-based applications that the company is pioneering. Tue, 16 Oct 2007 04:00:00 PST http://www.arrowres.com/publications/071009043129.html PASADENA, Calif.– October 9, 2007 – Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that its lead anti-cancer compound, IT-101, will be featured in a public television documentary series produced by Thirteen/WNET New York and the California Institute of Technology (Caltech). IT-101 is an experimental drug now undergoing clinical trials at City of Hope National Medical Center in Duarte, California. The series, named CURIOUS, consists of two one-hour documentaries that will air on public television beginning this month (check local listings.) Its focus is the research at the California Institute of Technology (Caltech) and the Jet Propulsion Lab (JPL). One of its episodes, titled Survival, chronicles the early research on IT-101 by Dr. Mark Davis, the Founder of Insert Therapeutics and Professor of Chemical Engineering at Caltech. The show also follows the progress of the first patient in the IT-101 clinical trial. Tue, 9 Oct 2007 04:00:00 PST http://www.arrowres.com/publications/071005043454.html PASADENA, California – October 5, 2007 – Arrowhead Research Corporation (NASDAQ: ARWR) announced today that its majority-owned subsidiary, Aonex Technologies, Inc. and partner Sandia National Laboratories have successfully demonstrated the growth of high-quality gallium nitride on Aonex's proprietary A-GaN™ substrates. Gallium nitride (GaN) and its alloys with indium nitride and aluminum nitride form the building blocks of devices such as blue, green, and white light emitting diodes (LEDs) and blue laser diodes. Aonex's A-GaN™ substrates provide a pathway for reducing the cost of GaN-based devices while also improving performance. According to recent studies by Strategies Unlimited, the market for advanced substrates like A-GaN™ for gallium nitride devices is expected to grow to more than $440 million by 2010. Much of this growth will be driven by the blue laser diode market which Strategy Analytics expects to grow to over $1 billion by 2011, a compounded average annual growth rate of 103% over the next four years. Strategy Analytics forecasts the market for LEDs to grow from its current value of $5.2B to $8.9B by 2011. Fri, 5 Oct 2007 04:00:00 PST http://www.arrowres.com/publications/070925040250.html PASADENA, California – September 25, 2007 – Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication of a study in the Proceedings of the National Academy of Sciences (PNAS) the scientific journal of the NAS. Dr. Mark Davis, professor of chemical engineering at Caltech, and his colleagues at UCLA used Calando’s proprietary RONDEL™ polymer technology for delivering siRNA in mice. Dr. Davis is a founder and Chief Scientific Advisor to Calando and to Insert Therapeutics, Inc., another majority-owned subsidiary of Arrowhead. Tue, 25 Sep 2007 04:00:00 PST http://www.arrowres.com/publications/070924042847.html PASADENA, California – September 24, 2007 – Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today the issuance of a patent covering its lead oncology product, IT-101. IT-101 is a conjugate of Insert’s proprietary drug delivery molecule, Cyclosert™, and the potent anti-cancer compound camptothecin. The newly-issued United States Patent No. 7,270,808 entitled “Cyclodextrin-based polymers for therapeutic delivery” covers Cyclosert-linked prodrugs, including camptothecin and camptothecin derivatives. Mon, 24 Sep 2007 04:00:00 PST http://www.arrowres.com/publications/070912043145.html MENLO PARK, California – September 12, 2007 – Unidym Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that U.S. Patent No. 7,265,174 has been issued by the U.S. Patent and Trademark Office. With respect to transparent conductive films, Clemson University has exclusively licensed this patent to Unidym. Unidym is a leader in the development and manufacture of carbon nanotubes for applications in the electronics industry. Unidym, which recently merged with Carbon Nanotechnologies, Inc. (CNI), possesses a foundational patent portfolio that covers nearly every aspect of carbon nanotube manufacturing and processing. Wed, 12 Sep 2007 04:00:00 PST